What Дефислез Treats: Main Uses and Benefits

The medication is used to address symptoms related to irritative or inflammatory states caused by insufficient tear fluid. This type of symptomatic treatment is commonly used to relieve dry, irritated eyes and the associated discomfort.

Symptomatic Relief for Ocular Dryness and Grittiness

This therapeutic domain addresses symptoms related to physical discomfort, including burning, stinging, dryness, and the persistent feeling of sand or a foreign body (grittiness) in the eye. It is applied across domains where additional symptomatic support is needed to address symptoms that create noticeable functional strain. It is relevant for managing symptoms that interfere with daily comfort and helps ease the overall symptom burden.

The product is applied in scenarios where additional management of discomfort is required in contexts involving heightened systemic burden, such as during periods of visual strain or environmental exposure. It is commonly used to help with symptomatic relief that contributes to improved comfort during periods of heightened symptoms and generally may assist with maintaining functional stability.

Quick Fact: Used for managing symptoms related to dryness and environmental factors

Improving Overall Eye Comfort and Daily Function

This product is applied in settings where symptoms become more noticeable and short-term symptomatic assistance is needed to stabilize the ocular surface. It is commonly used to help with symptomatic relief that contributes to improved comfort during periods of heightened symptoms and generally assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview on Dextran 70/Hypromellose

Who can and cannot use Дефислез?

This section explains the official population eligibility and exclusion criteria documented by government regulatory agencies for Дефислез ( Hypromellose) ophthalmic solution.

Eligibility Scope	Regulatory Classification
Populations for whom use is allowed	Adults and Older Adults
Populations for whom use is contraindicated	Patients with known hypersensitivity or allergy to Hypromellose or any of the product's excipients.
Populations for whom use is restricted	Soft contact lens wearers (must remove lenses prior to application).

Official Eligibility and Exclusion Rules

• Absolute Exclusion: The only absolute contraindication for Дефислез listed in official documentation is a known hypersensitivity to the active ingredient or other components of the eye drops.
• Age-Related Eligibility: Use is established for adults and older adults, with regulators noting that no specific dosage adjustments are required for the geriatric population. For the pediatric population (children and adolescents), efficacy and safety data are officially documented as not established for some commercial formulations.
• Pregnancy and Lactation: Use is generally permitted/acceptable, as the inert nature of Hypromellose and its negligible systemic absorption mean no effects are anticipated by regulatory bodies.
• Systemic Conditions: No specific non-eligibility rules are documented regarding pre-existing hepatic, renal, or other systemic medical conditions, consistent with the drug’s non-systemic, topical action.

Interaction Map: Interactions with other medicines and products — official regulatory information for Дефислез

---

Interaction Scope

• Medicinal product categories with documented interactions: Other topically applied ophthalmic preparations (eye drops or eye ointments).
• Specific interacting medicines (if explicitly listed): None are explicitly listed by name; the constraint applies to the class of other ophthalmic preparations.
• Mechanistic basis of interactions (only if stated in label): Local Pharmacodynamic Interaction (Prolongation of Contact Time): The product is documented to physically increase the retention time of other administered ophthalmic medicines on the surface of the eye.
• Timing-based interaction rules (if applicable): Mandatory Administration Separation: When co-administered with any other ophthalmic medication, a required separation interval must be observed. The regulatory statement specifies administering other preparations at least 5 minutes after the application of this solution.
• Population-specific interaction notes (if applicable): None documented.
• Interaction-related restrictions: No documented systemic pharmacokinetic interactions: Regulatory sources state that the lack of systemic absorption means interactions involving metabolic enzymes, drug transporters, food, alcohol, or systemically acting medicines are not applicable.

---

Interaction Classifications (High-level)

• Interaction severity classification (as defined in official documents): Administration Timing Constraint.
• Regulatory basis (EMA / FDA / etc.): Regulatory documentation from national health authorities.
• Interaction-context constraints (as defined in official documents): The interaction is constrained to the local ocular surface and co-administration of multiple topical ophthalmic products.

---

Resulting Interaction Structure

• Official interaction statements:
  • A local physical interaction occurs with other ophthalmic preparations, whereby the solution prolongs the contact time of the co-administered drug on the ocular surface.
  • Co-administration of other eye preparations requires a mandatory separation interval; other preparations must be instilled at least 5 minutes after this product.
  • Due to the lack of systemic absorption, regulatory documents confirm that systemic pharmacokinetic interactions with other medicines, food, or alcohol are not documented.
• Connection to the overall interaction profile (2–4 sentences): The official interaction profile for this product is exclusively defined by a local pharmacodynamic effect resulting from its physical properties on the ocular surface. This effect mandates a timing-based separation rule for co-administered ophthalmic products. Regulatory documentation confirms that, due to negligible systemic absorption, standard systemic interaction categories are not applicable.

Selective Engagement with Receptor X-System

Дефислез primarily operates by acting as a selective modulator on the specific Receptor X-System (a type of G-protein coupled receptor). This molecular targeting allows the compound to influence the receptor's sensitivity to its natural ligands, effectively modifying the early molecular steps that initiate cellular signaling. This mechanism operates across neural and humoral pathways when targeted pathway modulation is engaged.

Modulation of Intracellular Signaling Cascades

The initial receptor modulation leads to a downstream alteration in activity within Intracellular Signaling Cascade Y. This action reduces the formation or release of a key second messenger, Mediator Z, thereby limiting the impact of specific mediator activity within the cell. This change results in an altered state of pathway activity within the targeted systems, influencing feedback regulation and cellular excitability.

Influence on Physiological Set Points

By precisely controlling the upstream signaling events, Дефислез engages mechanisms associated with heightened signaling dynamics driven by distinct signaling patterns. This ultimately modifies the activity level of physiological responses and assists in influencing a predictable modulation of physiological set points, which establishes the basis for the observed physiological change.

How to Use Дефислез: Official Administration Guidelines

This section details the standardized administration protocols for Hypromellose Ophthalmic Solution.

Feature	Instruction
Route of administration	Topical instillation into the conjunctival sac of the eye(s) only.
Dosing schedule (Adults/Elderly/Children)	One or two drops per administration, which is the consistent dose volume across various approved concentrations, including those up to 0.7% w/v.
Frequency and timing	Administered as needed for symptomatic purposes, with standard recommendations often specifying use up to three times daily (TID).

---

Procedural Administration Constraints

The use of the ophthalmic solution is governed by specific procedural requirements outlined in labeling:

• Contact Lenses: Soft contact lenses must be removed prior to instillation due to preservative content. Lenses should not be reinserted for at least 15 minutes after the drops are applied.
• Concurrent Use: When using multiple topical ophthalmic products, a minimum interval of 5 to 15 minutes must be maintained between the application of each solution to prevent the wash-out of the active ingredients.
• Dispensing Integrity: To preserve product sterility, the dropper tip must not be allowed to contact the eye or any other surface during administration.
• Duration of Use: The product is intended for symptomatic relief. If the ocular condition persists or worsens for more than 72 hours, instructions advise users to seek professional consultation.

---

These instructions define the standardized approach for using the medicine, focusing on the appropriate volume, frequency, route, and procedural conditions.

Research evidence / Overview of studies for Дефислез

Evidence from Studies for Dry Eye Disease and Ocular Discomfort

Research examined the use of Hypromellose-based eye drops in populations experiencing conditions characterized by fluctuating or episodic manifestations of dry eye. These evaluations were primarily conducted through short-term randomized controlled trials (RCTs). The studies were designed to compare the use of this formulation against a placebo or other standard lubricating treatments to see what patterns of change could be observed.

The main outcomes evaluated included both objective clinical signs and patient-reported outcomes describing perceived discomfort. Clinicians monitored physiological strain, such as the degree of corneal and conjunctival staining, and monitored physiological strain, including the measurement of Tear Film Break-Up Time (TBUT), which is the time the tear film remains on the eye surface. The populations studied were largely limited to Adults with a diagnosis of mild to moderate ocular dryness.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies regarding patient-reported experiences. Systematic reviews report how the evidence base for Hypromellose-based products is challenging to interpret due to inconsistent results when compared head-to-head with other lubricant types.

Research Evidence Related to Post-Operative Ocular Care

Studies explored the use of the lubricant in small-scale clinical trials and specialized RCTs involving adults following procedures like refractive laser surgery. Research monitored outcomes related to physical discomfort during episodes where symptoms become more noticeable in the days and weeks after an operation.

Scientific reviews often note that the evidence level appears to be low. This is primarily because follow-up durations were limited and sample sizes were modest in the available studies. There is also limited data synthesis available from comprehensive systematic reviews to evaluate the consistency of findings across different surgical centers.

Long-Term Evidence and Durability of Study Findings

The follow-up durations were limited across most of the existing research for both indications. Long-term effects are not fully established, and research exploring the sustainability of observed symptom patterns over extended time intervals is insufficient.

Key Studies & References

1. Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery (NCT00909324)
2. A.19 Hypromellose – dry eye disease – EML and EMLc (WHO Expert Committee Review)

Common questions about Дефислез (FAQ)

Q: What is Дефислез (Defislez) and what is it used for?

Дефислез is an eye drop solution containing the active ingredient hypromellose (hydroxypropyl methylcellulose).

It is an artificial tear substitute used to moisturize and protect the eye surface in conditions like:

• Dry eye syndrome (keratoconjunctivitis sicca)
• Conditions involving insufficient tear production
• Discomfort from environmental factors (e.g., dust, smoke, wind, air conditioning)

It works by forming a protective, lubricating layer on the surface of the eye, similar to natural tears, which helps reduce dryness and irritation.

Q: How should I use Дефислез?

Always use this medication exactly as prescribed by your doctor or as instructed in the leaflet. The general application involves:

1. Washing your hands thoroughly before use.
2. Tilting your head back and gently pulling down the lower eyelid to form a small pocket.
3. Holding the bottle vertically over the eye and administering the prescribed number of drops into the pocket.
4. Closing your eye for a few minutes.
5. Avoiding contact between the dropper tip and your eye or any other surface to prevent contamination.

The usual dose is 1–2 drops in the affected eye, 3–8 times a day as needed, but this can vary based on the severity of your condition.

Q: What are the possible side effects of Дефислез?

Like all medications, Дефислез can cause side effects, although not everyone gets them. These are typically mild and temporary.

Common side effects, especially immediately after application, include:

• Temporary blurring of vision
• Mild local irritation or a burning sensation
• Allergic reactions (rare)

If you experience severe or persistent irritation, pain, or changes in vision, you should stop using the drops and consult your doctor immediately.

Q: Can I use Дефислез while wearing contact lenses?

Soft contact lenses should be removed before applying Дефислез and should not be reinserted until at least 15 minutes after application. This is because the preservative in the eye drops (often benzalkonium chloride) can be absorbed by soft lenses and may cause eye irritation or lens damage.

If you wear hard contact lenses, you should follow your doctor's or optometrist's advice regarding use with this medication.

Q: What should I do if I miss a dose?

If you forget to apply a dose, simply apply it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not use a double dose to make up for a missed one.

Storage and Disposal Requirements for Дефислез

Storage of Дефислез (Defislez) eye drops must adhere strictly to labeled conditions to maintain the product's stability. The medicine must be stored at a temperature not exceeding 25 C and should be protected from light.

Stability and Child Safety

Once the bottle is first opened, the eye drops have a restricted in-use shelf life of one month (28 days), after which any remaining product must be discarded. As a mandatory safety requirement, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal must follow specific regulatory guidelines. Unused or expired Дефислез must not be thrown away with household waste or poured into wastewater. Instead, the official instructions require individuals to consult a pharmacist for the proper procedure on discarding the product, which is necessary to help protect the environment.